South San Francisco, United States
Tacit Therapeutics is an innovative player in the Biotechnology and Health Care sectors, established in 2021. The company is addressing critical unmet needs by developing RNA-targeting treatments for severe diseases. Tacit Therapeutics' approach involves using pre-existing components of human cells, potentially offering a revolutionary method to repair mutated genes that is inherently non-immunogenic and broadly applicable.
Based in the United States, Tacit Therapeutics is positioning itself as a leader in gene therapy innovation. Their recent investment milestone demonstrates market confidence in their disruptive potential. On June 8, 2022, the company secured a $9.50M venture round investment from Eisai Innovation Inc, showcasing strategic support from established industry participants. With such backing, Tacit Therapeutics is poised for impactful growth, underlining its potential appeal to investors focused on groundbreaking advancements in healthcare.
